XELJANZ (Pfizer Australia Pty Ltd)
Product name
XELJANZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
193 working days (255)
Active ingredients
tofacitinib citrate
Registration type
EOI
Indication
XELJANZ (tablets) is now also indicated for:
Psoriatic Arthritis
- XELJANZ in combination with conventional synthetic DMARDs is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to a prior DMARD therapy.